B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 600 KRW -2.13% Market Closed
Market Cap: 469.1B KRW
Have any thoughts about
BioNote Inc?
Write Note

BioNote Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioNote Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
B
BioNote Inc
KRX:377740
Other Equity
â‚©30B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Other Equity
â‚©207.2B
CAGR 3-Years
42%
CAGR 5-Years
39%
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Other Equity
â‚©10.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Other Equity
-â‚©348.7B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Other Equity
â‚©3.6B
CAGR 3-Years
20%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Other Equity
â‚©6.1B
CAGR 3-Years
27%
CAGR 5-Years
30%
CAGR 10-Years
N/A
No Stocks Found

BioNote Inc
Glance View

Market Cap
469.5B KRW
Industry
Biotechnology

BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.

Intrinsic Value
6 138.02 KRW
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is BioNote Inc's Other Equity?
Other Equity
30B KRW

Based on the financial report for Dec 31, 2023, BioNote Inc's Other Equity amounts to 30B KRW.

What is BioNote Inc's Other Equity growth rate?
Other Equity CAGR 1Y
1 273%

Over the last year, the Other Equity growth was 1 273%.

Back to Top